NASDAQ:CRSP - CRISPR Therapeutics Stock Price, Price Target & More

$46.50 -0.77 (-1.63 %)
(As of 04/25/2018 08:54 AM ET)
Previous Close$47.27
Today's Range$46.50 - $46.50
52-Week Range$13.50 - $61.24
Volume562 shs
Average Volume1.15 million shs
Market Capitalization$2.34 billion
P/E Ratio-27.64
Dividend YieldN/A
Beta3.56

About CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics logoCRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-61-228-7800

Debt

Debt-to-Equity RatioN/A
Current Ratio17.12%
Quick Ratio17.12%

Price-To-Earnings

Trailing P/E Ratio-27.64
Forward P/E Ratio-16.49
P/E GrowthN/A

Sales & Book Value

Annual Sales$41 million
Price / Sales53.50
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book11.37

Profitability

EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-166.74%
Return on Equity-35.07%
Return on Assets-23.15%

Miscellaneous

Employees127
Outstanding Shares47,170,000

How to Become a New Pot Stock Millionaire

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.02. The firm had revenue of $2.39 million for the quarter, compared to analysts' expectations of $3.61 million. CRISPR Therapeutics had a negative return on equity of 35.07% and a negative net margin of 166.74%. The firm's revenue for the quarter was up 54.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.77) earnings per share. View CRISPR Therapeutics' Earnings History.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for CRISPR Therapeutics.

What price target have analysts set for CRSP?

9 equities research analysts have issued twelve-month price targets for CRISPR Therapeutics' shares. Their forecasts range from $51.00 to $86.00. On average, they anticipate CRISPR Therapeutics' share price to reach $63.95 in the next year. View Analyst Ratings for CRISPR Therapeutics.

What are Wall Street analysts saying about CRISPR Therapeutics stock?

Here are some recent quotes from research analysts about CRISPR Therapeutics stock:
  • 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (3/13/2018)
  • 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)
  • 3. Chardan Capital analysts commented, "We calculated the CRISPR sector enterprise value (EV) by discounting Chardan target sector EVs of companies in the AAV (assumed 3 years ahead) and small RNA (assumed 3 years ahead) gene therapy sectors; we applied a discount rate of 20%, which we believe is reasonable for preclinical biotech firms. Giving CRSP a CRISPR sector valuation distribution of 15% of the calculated CRISPR sector EV (based on our view of the firm’s relative IP weakness balanced by potential first entry of a CRISPR therapy into the clinic) and adding $272.3 mm in cash, we project a CRSP market cap range of $866 mm-$901 mm." (8/14/2017)

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totalling 2,403,752 shares, an increase of 74.9% from the February 28th total of 1,374,219 shares. Based on an average daily volume of 1,434,160 shares, the short-interest ratio is currently 1.7 days. Currently, 12.4% of the shares of the stock are short sold.

Who are some of CRISPR Therapeutics' key competitors?

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the folowing people:
  • Dr. Rodger Novak, Founder & Chairman (Age 51)
  • Mr. Marc A. Becker, Former CFO & Sr. VP (Age 46)
  • Dr. Kala Subramanian Ph.D., Chief of Staff and Sr. VP of Strategic Devel. & Operations (Age 51)
  • N. Anthony Coles Jr., Sr. Advisor (Age 58)
  • Dr. Samarth Kulkarni, Chief Exec. Officer (Age 39)

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Has CRISPR Therapeutics been receiving favorable news coverage?

News headlines about CRSP stock have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CRISPR Therapeutics earned a news sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the company an impact score of 46.68 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $46.50.

How big of a company is CRISPR Therapeutics?

CRISPR Therapeutics has a market capitalization of $2.34 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. CRISPR Therapeutics employs 127 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.


MarketBeat Community Rating for CRISPR Therapeutics (CRSP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  221
MarketBeat's community ratings are surveys of what our community members think about CRISPR Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CRISPR Therapeutics (NASDAQ:CRSP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for CRISPR Therapeutics in the last 12 months. Their average twelve-month price target is $63.95, suggesting that the stock has a possible upside of 37.53%. The high price target for CRSP is $86.00 and the low price target for CRSP is $51.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.632.672.50
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $63.95$53.5333$22.8125$23.0833
Price Target Upside: 37.53% upside0.31% downside32.41% downside23.18% upside

CRISPR Therapeutics (NASDAQ:CRSP) Consensus Price Target History

Price Target History for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/6/2018Goldman SachsInitiated CoverageBuy -> Buy$86.00HighView Rating Details
3/9/2018SunTrust BanksReiterated RatingBuy$65.00HighView Rating Details
3/9/2018Piper JaffrayReiterated RatingOverweight$67.00 -> $53.70HighView Rating Details
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$69.00HighView Rating Details
3/7/2018BarclaysBoost Price TargetOverweight -> Overweight$29.00 -> $59.00LowView Rating Details
2/28/2018CitigroupBoost Price TargetNeutral -> Neutral$20.00 -> $51.00MediumView Rating Details
12/21/2017OppenheimerReiterated RatingHoldHighView Rating Details
12/10/2017CannReiterated RatingHoldHighView Rating Details
8/14/2017Chardan CapitalReiterated RatingBuyMediumView Rating Details
11/14/2016GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

CRISPR Therapeutics (NASDAQ:CRSP) Earnings History and Estimates Chart

Earnings by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Earnings Estimates

2018 EPS Consensus Estimate: ($3.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.67)($0.67)($0.67)
Q2 20181($0.67)($0.67)($0.67)
Q3 20181($0.72)($0.72)($0.72)
Q4 20181($1.01)($1.01)($1.01)

CRISPR Therapeutics (NASDAQ CRSP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.67)N/AView Earnings Details
11/8/2017Q3($0.60)($0.62)$3.61 million$2.39 millionViewN/AView Earnings Details
8/10/20176/30/2017($0.62)($0.56)$3.29 million$3.60 millionViewN/AView Earnings Details
5/11/20173/31/2017($0.60)($0.54)$2.70 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.38)($0.40)$2.34 millionViewN/AView Earnings Details
11/22/2016Q3 2016($2.77)$1.55 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CRISPR Therapeutics (NASDAQ:CRSP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CRISPR Therapeutics (NASDAQ CRSP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 39.98%
Institutional Ownership Percentage: 26.62%
Insider Trading History for CRISPR Therapeutics (NASDAQ:CRSP)
Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ CRSP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/23/2018Bradley J Phd BolzonDirectorSell101,994$50.68$5,169,055.9243,986View SEC Filing  
1/16/2018Tyler Dylan-HydeInsiderSell66,000$28.03$1,849,980.0025,204View SEC Filing  
1/5/2018Aktiengesellschaft BayerMajor ShareholderBuy527,472$22.75$11,999,988.00View SEC Filing  
1/5/2018Kurt Von EmsterDirectorSell92,337$26.96$2,489,405.52View SEC Filing  
1/2/2018Kurt Von EmsterDirectorSell37,754$26.76$1,010,297.04View SEC Filing  
1/2/2018Tyler Dylan-HydeInsiderSell38,000$21.64$822,320.0070,204View SEC Filing  
12/29/2017Tyler Dylan-HydeInsiderSell31,000$22.72$704,320.00View SEC Filing  
12/28/2017Tyler Dylan-HydeInsiderSell700$21.75$15,225.00115,904View SEC Filing  
12/22/2017Thomas WoiwodeDirectorSell3,059$20.29$62,067.114,959View SEC Filing  
12/22/2017Tyler Dylan-HydeInsiderSell15,000$20.55$308,250.00115,204View SEC Filing  
12/15/2017Tyler Dylan-HydeInsiderSell15,000$18.90$283,500.00130,204View SEC Filing  
12/4/2017Corp /De/ CelgeneMajor ShareholderSell1,112,446$18.98$21,114,225.08View SEC Filing  
12/1/2017Corp /De/ CelgeneMajor ShareholderSell87,991$19.10$1,680,628.10View SEC Filing  
11/29/2017Corp /De/ CelgeneMajor ShareholderSell4,263$19.25$82,062.75View SEC Filing  
11/27/2017Corp /De/ CelgeneMajor ShareholderSell27,990$19.75$552,802.50View SEC Filing  
11/27/2017Thomas WoiwodeDirectorSell200$20.24$4,048.008,218View SEC Filing  
11/24/2017Corp /De/ CelgeneMajor ShareholderSell26,010$20.00$520,200.00View SEC Filing  
11/24/2017Thomas WoiwodeDirectorSell1,700$20.21$34,357.008,218View SEC Filing  
11/22/2017Corp /De/ CelgeneMajor ShareholderSell256,000$19.76$5,058,560.00View SEC Filing  
11/20/2017Corp /De/ CelgeneMajor ShareholderSell158,718$19.02$3,018,816.36View SEC Filing  
11/17/2017Corp /De/ CelgeneMajor ShareholderSell51,282$18.44$945,640.08View SEC Filing  
11/15/2017Corp /De/ CelgeneMajor ShareholderSell15,000$17.67$265,050.00View SEC Filing  
11/13/2017Corp /De/ CelgeneMajor ShareholderSell65,093$17.76$1,156,051.68View SEC Filing  
11/10/2017Corp /De/ CelgeneMajor ShareholderSell10,000$17.28$172,800.00View SEC Filing  
11/8/2017Corp /De/ CelgeneMajor ShareholderSell16,875$18.06$304,762.50View SEC Filing  
11/6/2017Corp /De/ CelgeneMajor ShareholderSell79,327$18.89$1,498,487.03View SEC Filing  
11/3/2017Corp /De/ CelgeneMajor ShareholderSell22,759$19.10$434,696.90View SEC Filing  
9/5/2017Rodger NovakCEOSell18,470$20.76$383,437.201,148,007View SEC Filing  
8/30/2017Rodger NovakCEOSell75,795$20.25$1,534,848.751,232,697View SEC Filing  
8/30/2017Samarth KulkarniInsiderSell27,154$20.08$545,252.32110,893View SEC Filing  
8/28/2017Kurt Von EmsterDirectorSell88,011$19.79$1,741,737.69View SEC Filing  
8/25/2017Kurt Von EmsterDirectorSell22,781$19.42$442,407.02View SEC Filing  
8/23/2017Kurt Von EmsterDirectorSell17,989$18.53$333,336.17View SEC Filing  
8/21/2017Kurt Von EmsterDirectorSell3,150$18.52$58,338.00View SEC Filing  
8/17/2017Kurt Von EmsterDirectorSell34,141$19.06$650,727.46View SEC Filing  
8/15/2017Kurt Von EmsterDirectorSell55,569$19.59$1,088,596.71View SEC Filing  
8/8/2017Kurt Von EmsterDirectorSell35,473$18.63$660,861.99View SEC Filing  
8/8/2017Tyler Dylan-HydeInsiderSell15,000$18.57$278,550.00167,727View SEC Filing  
8/4/2017Kurt Von EmsterDirectorSell50,477$17.81$898,995.37View SEC Filing  
8/1/2017Kurt Von EmsterDirectorSell5,512$17.51$96,515.12View SEC Filing  
7/28/2017Kurt Von EmsterDirectorSell41,312$17.63$728,330.56View SEC Filing  
7/26/2017Kurt Von EmsterDirectorSell32,930$17.60$579,568.00View SEC Filing  
7/14/2017Kurt Von EmsterDirectorSell69,859$16.84$1,176,425.56View SEC Filing  
7/12/2017Kurt Von EmsterDirectorSell31,992$16.56$529,787.52View SEC Filing  
7/5/2017Kurt Von EmsterDirectorSell4,254$16.26$69,170.04View SEC Filing  
6/29/2017Kurt Von EmsterDirectorSell43,202$16.90$730,113.80View SEC Filing  
6/27/2017Kurt Von EmsterDirectorSell81,435$17.08$1,390,909.80View SEC Filing  
6/23/2017Kurt Von EmsterDirectorSell32,368$16.23$525,332.64View SEC Filing  
6/22/2017Rodger NovakCEOSell10,825$15.37$166,380.251,225,830View SEC Filing  
6/21/2017Rodger NovakCEOSell30,222$15.01$453,632.221,230,397View SEC Filing  
6/9/2017Rodger NovakCEOSell5,303$15.02$79,651.061,219,208View SEC Filing  
5/30/2017Rodger NovakCEOSell3,650$15.02$54,823.001,218,655View SEC Filing  
5/17/2017Rodger NovakCEOSell50,000$16.26$813,000.001,239,082View SEC Filing  
5/5/2017Rodger NovakCEOSell616$16.92$10,422.721,215,621View SEC Filing  
5/4/2017Rodger NovakCEOSell49,384$16.30$804,959.201,230,929View SEC Filing  
4/28/2017Tyler Dylan-HydeInsiderSell21,639$16.78$363,102.42180,495View SEC Filing  
4/27/2017Samarth KulkarniInsiderSell5,481$16.76$91,861.56137,322View SEC Filing  
4/25/2017Samarth KulkarniInsiderSell11,615$16.78$194,899.70137,047View SEC Filing  
4/20/2017Rodger NovakCEOSell50,000$17.88$894,000.001,262,711View SEC Filing  
4/20/2017Tyler Dylan-HydeInsiderSell10,177$17.71$180,234.67200,274View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/24/2016Simeon GeorgeDirectorBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CRISPR Therapeutics (NASDAQ CRSP) News Headlines

Source:
DateHeadline
CRISPR Therapeutics (CRSP) Rating Lowered to Buy at BidaskClubCRISPR Therapeutics (CRSP) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 25 at 12:26 AM
CRISPR Therapeutics (CRSP) Director Sells $5,169,055.92 in StockCRISPR Therapeutics (CRSP) Director Sells $5,169,055.92 in Stock
www.americanbankingnews.com - April 24 at 10:22 PM
-$0.67 Earnings Per Share Expected for CRISPR Therapeutics (CRSP) This Quarter-$0.67 Earnings Per Share Expected for CRISPR Therapeutics (CRSP) This Quarter
www.americanbankingnews.com - April 24 at 9:16 PM
Geron Corporation: The Clock Is TickingGeron Corporation: The Clock Is Ticking
finance.yahoo.com - April 23 at 4:26 PM
What Are Analysts Expecting From CRISPR Therapeutics AG (NASDAQ:CRSP) Over The Next Few Years?What Are Analysts Expecting From CRISPR Therapeutics AG (NASDAQ:CRSP) Over The Next Few Years?
finance.yahoo.com - April 23 at 9:10 AM
Big Week in Tech for Amazon, Alphabet and MicrosoftBig Week in Tech for Amazon, Alphabet and Microsoft
finance.yahoo.com - April 22 at 5:17 PM
Rounds Report: Crispr Rallied While Akcea Became An Acquisition ProspectRounds Report: Crispr Rallied While Akcea Became An Acquisition Prospect
seekingalpha.com - April 20 at 9:40 AM
Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based InnovatorsRounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators
seekingalpha.com - April 20 at 9:40 AM
CRISPR Therapeutics (CRSP) Given Market Perform Rating by Oppenheimer AnalystsCRISPR Therapeutics (CRSP) Given Market Perform Rating by Oppenheimer Analysts
www.americanbankingnews.com - April 17 at 7:01 PM
Preclinical data show potential effectiveness of CRISPR Therapeutics off-the-shelf CAR-T cells; shares up 2% after hoursPreclinical data show potential effectiveness of CRISPR Therapeutics' off-the-shelf CAR-T cells; shares up 2% after hours
seekingalpha.com - April 17 at 9:49 AM
CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
finance.yahoo.com - April 16 at 4:25 PM
Portfolio Review: Continue Market Outperformance In Q1 2018Portfolio Review: Continue Market Outperformance In Q1 2018
seekingalpha.com - April 14 at 4:10 PM
CRISPR Therapeutics (CRSP) Given Average Recommendation of "Buy" by BrokeragesCRISPR Therapeutics (CRSP) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 14 at 1:25 AM
CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
finance.yahoo.com - April 13 at 9:52 AM
Investors Purchase High Volume of CRISPR Therapeutics Put Options (CRSP)Investors Purchase High Volume of CRISPR Therapeutics Put Options (CRSP)
www.americanbankingnews.com - April 13 at 6:13 AM
CRISPR Therapeutics (CRSP) Receives Buy Rating from Chardan CapitalCRISPR Therapeutics (CRSP) Receives Buy Rating from Chardan Capital
www.americanbankingnews.com - April 10 at 5:03 PM
 Analysts Anticipate CRISPR Therapeutics (CRSP) Will Post Quarterly Sales of $2.45 Million Analysts Anticipate CRISPR Therapeutics (CRSP) Will Post Quarterly Sales of $2.45 Million
www.americanbankingnews.com - April 9 at 1:08 AM
-$0.67 EPS Expected for CRISPR Therapeutics (CRSP) This Quarter-$0.67 EPS Expected for CRISPR Therapeutics (CRSP) This Quarter
www.americanbankingnews.com - April 7 at 9:18 PM
CRISPR Therapeutics (CRSP) Coverage Initiated by Analysts at Goldman SachsCRISPR Therapeutics (CRSP) Coverage Initiated by Analysts at Goldman Sachs
www.americanbankingnews.com - April 6 at 10:49 AM
Goldman bullish on CRISPR Therapeutics, sees 100% upsideGoldman bullish on CRISPR Therapeutics, sees 100% upside
seekingalpha.com - April 6 at 9:55 AM
CRISPR Therapeutics (CRSP) Upgraded to Hold at ValuEngineCRISPR Therapeutics (CRSP) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 5:16 PM
Crispr Therapeutics (CRSP) Given "Hold" Rating at CannCrispr Therapeutics (CRSP) Given "Hold" Rating at Cann
www.americanbankingnews.com - March 31 at 9:55 PM
Crispr Therapeutics (CRSP) Stock Rating Upgraded by BidaskClubCrispr Therapeutics (CRSP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM
Crispr Therapeutics AG (CRSP) Short Interest UpdateCrispr Therapeutics AG (CRSP) Short Interest Update
www.americanbankingnews.com - March 30 at 3:38 AM
Piper Jaffray Reiterates "Buy" Rating for Crispr Therapeutics (CRSP)Piper Jaffray Reiterates "Buy" Rating for Crispr Therapeutics (CRSP)
www.americanbankingnews.com - March 29 at 6:22 PM
CRISPR Therapeutics (CRSP) Presents at Needham and Company 17th Annual Healthcare Conference - SlideshowCRISPR Therapeutics (CRSP) Presents at Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:28 PM
Crispr Therapeutics (CRSP) Upgraded to Buy by SunTrust BanksCrispr Therapeutics (CRSP) Upgraded to Buy by SunTrust Banks
www.americanbankingnews.com - March 26 at 8:14 PM
CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual PropertyCRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property
finance.yahoo.com - March 26 at 4:19 PM
Crispr Therapeutics (CRSP) Stock Rating Upgraded by TheStreetCrispr Therapeutics (CRSP) Stock Rating Upgraded by TheStreet
www.americanbankingnews.com - March 24 at 12:28 AM
Crispr Therapeutics AG (CRSP) Expected to Post Quarterly Sales of $2.45 MillionCrispr Therapeutics AG (CRSP) Expected to Post Quarterly Sales of $2.45 Million
www.americanbankingnews.com - March 23 at 1:50 AM
Does Crispr Therapeutics AG Deserve This Massive Rally? - Investorplace.comDoes Crispr Therapeutics AG Deserve This Massive Rally? - Investorplace.com
investorplace.com - March 21 at 4:25 PM
Analyzing CRISPR Therapeutics Q4 And Full-Year 2017 ResultsAnalyzing CRISPR Therapeutics' Q4 And Full-Year 2017 Results
seekingalpha.com - March 20 at 4:21 PM
Crispr Therapeutics AG (CRSP) Receives Consensus Recommendation of "Buy" from BrokeragesCrispr Therapeutics AG (CRSP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 20 at 1:46 AM
Does Crispr Therapeutics AG Deserve This Massive Rally?Does Crispr Therapeutics AG Deserve This Massive Rally?
investorplace.com - March 19 at 1:24 PM
Today’s Research Reports on Trending Tickers: CRISPR Therapeutics and Syndax PharmaceuticalsToday’s Research Reports on Trending Tickers: CRISPR Therapeutics and Syndax Pharmaceuticals
finance.yahoo.com - March 15 at 9:23 AM
Crispr Therapeutics (CRSP) Upgraded at Zacks Investment ResearchCrispr Therapeutics (CRSP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 13 at 8:00 PM
Record Revenue Growth & Imminent Nasdaq Listing Could Spell Big Upside for Unknown Orgenesis (ORGS)Record Revenue Growth & Imminent Nasdaq Listing Could Spell Big Upside for Unknown Orgenesis (ORGS)
finance.yahoo.com - March 13 at 9:47 AM
Heres Why CRISPR Therapeutics AG Gained as Much as 14% TodayHere's Why CRISPR Therapeutics AG Gained as Much as 14% Today
www.msn.com - March 10 at 9:37 AM
Crispr Therapeutics (CRSP) Given "Overweight" Rating at Piper Jaffray CompaniesCrispr Therapeutics (CRSP) Given "Overweight" Rating at Piper Jaffray Companies
www.americanbankingnews.com - March 9 at 11:24 PM
Crispr Therapeutics (CRSP) Receives "Buy" Rating from SunTrust BanksCrispr Therapeutics (CRSP) Receives "Buy" Rating from SunTrust Banks
www.americanbankingnews.com - March 9 at 9:04 PM
Heres Why CRISPR Therapeutics AG Gained as Much as 14% Today - Motley FoolHere's Why CRISPR Therapeutics AG Gained as Much as 14% Today - Motley Fool
www.fool.com - March 9 at 5:29 PM
Here's Why CRISPR Therapeutics AG Gained as Much as 14% TodayHere's Why CRISPR Therapeutics AG Gained as Much as 14% Today
finance.yahoo.com - March 9 at 5:29 PM
Crispr Therapeutics (CRSP) Receives New Coverage from Analysts at JMP SecuritiesCrispr Therapeutics (CRSP) Receives New Coverage from Analysts at JMP Securities
www.americanbankingnews.com - March 8 at 11:40 PM
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial ResultsCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 5:20 PM
2018 is a big year for gene editing. Here’s what to watch for locally.2018 is a big year for gene editing. Here’s what to watch for locally.
www.bizjournals.com - March 8 at 9:50 AM
Crispr Therapeutics (CRSP) PT Raised to $59.00 at BarclaysCrispr Therapeutics (CRSP) PT Raised to $59.00 at Barclays
www.americanbankingnews.com - March 7 at 5:26 PM
Heres Why Crispr Therapeutics AG Jumped Again in FebruaryHere's Why Crispr Therapeutics AG Jumped Again in February
www.msn.com - March 4 at 5:21 PM
Zacks: Brokerages Anticipate Crispr Therapeutics AG (CRSP) to Announce -$0.71 Earnings Per ShareZacks: Brokerages Anticipate Crispr Therapeutics AG (CRSP) to Announce -$0.71 Earnings Per Share
www.americanbankingnews.com - March 4 at 5:16 PM
CRISPR Takes a Leap Forward With Huntingtons DiseaseCRISPR Takes a Leap Forward With Huntington's Disease
finance.yahoo.com - March 2 at 5:05 PM
Crispr Therapeutics (CRSP) Upgraded at ValuEngineCrispr Therapeutics (CRSP) Upgraded at ValuEngine
www.americanbankingnews.com - February 28 at 10:48 PM

SEC Filings

CRISPR Therapeutics (NASDAQ:CRSP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CRISPR Therapeutics (NASDAQ:CRSP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CRISPR Therapeutics (NASDAQ CRSP) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.